ArticleCancer communications (London, England)2023

Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer.

François Bertucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.